• Novartis revenues 2007-2020

Try our corporate solution for free!

(212) 419-8286

hadley.ward@statista.com

In 2020, the Swiss pharmaceutical company Novartis AG’s total revenue amounted to 48.7 billion U.S. dollars. This is an increase of some 1.3 billion U.S. dollars compared to the year before.

Novartis’ revenue by segment

Between 2014 and 2020, the multinational corporation, based in Basel, Switzerland, generated the bulk of its revenue through pharmaceuticals (innovative medicines): in 2020, the company made 39 billion U.S. dollars from this segment. That year Novartis generated close to one fifth of its revenue from its generic drug division (Sandoz).

Competitor Sanofi

Another global leader in the world of healthcare and pharmaceuticals is Sanofi, which is based in Paris, France. In 2019, the French company generated about 36 billion euros' worth of revenue. That same year, the majority of Sanofi’s revenue was earned through pharmaceuticals (roughly 25.7 billion euros), while the vaccine business segment generated just over 5.7 billion.

Novartis AG's total revenue from 2007 to 2020 (in billion U.S. dollars)

	Revenue in billion U.S. dollars
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Source

Show detailed source information?

Already a member?

Source

Release date

January 2021

More information

Region

Worldwide

Survey time period

2007 to 2020

Supplementary notes

This statistic was assembled from several editions of Novartis' annual report.
* With the 2015 Annual Report, values back to 2011 were restated, as a result of a series of transactions during 2015.
** During this year, eye care division Alcon was spun off and became an own company. Thus, Alcon's revenues are not included.

Open this statistic in...

French